Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT OTCMKTS:IPHYF NASDAQ:RLMD NASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.77-2.5%$2.88$2.56▼$6.44$552.31M0.253.93 million shs1.91 million shsIPHYFInnate Pharma$1.65$1.73$1.37▼$2.25$138.32M0.29N/AN/ARLMDRelmada Therapeutics$5.18-0.4%$6.41$0.55▼$8.00$545.43M0.412.46 million shs1.65 million shsSLNSilence Therapeutics$11.02-3.8%$8.32$4.19▼$11.90$540.84M1.38527,717 shs341,308 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.46%-3.48%-6.10%-2.64%-35.43%IPHYFInnate Pharma0.00%0.00%0.00%+10.00%+25.95%RLMDRelmada Therapeutics-0.38%-1.15%-20.49%-28.16%+620.45%SLNSilence Therapeutics-3.76%+4.95%+20.31%+43.12%+79.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.77-2.5%$2.88$2.56▼$6.44$552.31M0.253.93 million shs1.91 million shsIPHYFInnate Pharma$1.65$1.73$1.37▼$2.25$138.32M0.29N/AN/ARLMDRelmada Therapeutics$5.18-0.4%$6.41$0.55▼$8.00$545.43M0.412.46 million shs1.65 million shsSLNSilence Therapeutics$11.02-3.8%$8.32$4.19▼$11.90$540.84M1.38527,717 shs341,308 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.46%-3.48%-6.10%-2.64%-35.43%IPHYFInnate Pharma0.00%0.00%0.00%+10.00%+25.95%RLMDRelmada Therapeutics-0.38%-1.15%-20.49%-28.16%+620.45%SLNSilence Therapeutics-3.76%+4.95%+20.31%+43.12%+79.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.70Moderate Buy$15.71467.30% UpsideIPHYFInnate Pharma 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.75Moderate Buy$12.00131.66% UpsideSLNSilence Therapeutics 2.83Moderate Buy$55.00399.09% UpsideCurrent Analyst Ratings BreakdownLatest IPHYF, SLN, ALT, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026SLNSilence Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026SLNSilence Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/18/2026RLMDRelmada Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2026RLMDRelmada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/17/2026SLNSilence Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.006/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$36K14,963.69N/AN/A$1.99 per share1.39IPHYFInnate Pharma$10.19M13.57N/AN/A($0.29) per share-5.69RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ASLNSilence Therapeutics$839K620.42N/AN/A$1.32 per share8.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)IPHYFInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/A9/17/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)SLNSilence Therapeutics-$88.61M-$1.59N/AN/AN/A-8,943.86%-105.34%-52.79%8/6/2026 (Estimated)Latest IPHYF, SLN, ALT, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ALTAltimmune-$0.15N/AN/AN/A$0.00 millionN/A8/6/2026Q2 2026RLMDRelmada Therapeutics-$0.21N/AN/AN/AN/AN/A8/6/2026Q2 2026SLNSilence Therapeutics-$0.1387N/AN/AN/A$1.17 millionN/A5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/8/2026Q1 2026SLNSilence Therapeutics-$0.1850-$0.32-$0.1350-$0.33$1.26 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56IPHYFInnate PharmaN/A1.271.27RLMDRelmada TherapeuticsN/A18.2518.25SLNSilence TherapeuticsN/A9.839.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%IPHYFInnate PharmaN/ARLMDRelmada Therapeutics45.24%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%IPHYFInnate Pharma31.89%RLMDRelmada Therapeutics14.50%SLNSilence Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableSLNSilence Therapeutics10047.24 million45.82 millionNot OptionableIPHYF, SLN, ALT, and RLMD HeadlinesRecent News About These CompaniesSilence Therapeutics (NASDAQ:SLN) Reaches New 12-Month High - Time to Buy?July 23 at 4:19 AM | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Stock Price Up 6.9% - Here's WhyJuly 22 at 1:39 PM | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Reaches New 1-Year High - Should You Buy?July 19, 2026 | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Sets New 52-Week High - Here's WhyJuly 17, 2026 | marketbeat.comSilence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $55.00 Consensus PT from AnalystsJuly 17, 2026 | americanbankingnews.comSLN Stock Skyrockets 107% in Six Months: Here's What You Need to KnowJuly 16, 2026 | zacks.comSilence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?July 16, 2026 | zacks.comSilence Therapeutics (NASDAQ:SLN) Shares Up 10% - Here's What HappenedJuly 15, 2026 | marketbeat.comSilence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 12, 2026 | marketbeat.comSilence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)July 12, 2026 | seekingalpha.comSilence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline PotentialJune 30, 2026 | insidermonkey.comSilence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?June 25, 2026 | zacks.comSilence: 'Buy' Zerlasiran Program Shift And Divesiran Results August 2026June 12, 2026 | seekingalpha.comSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia VeraJune 11, 2026 | businesswire.comSilence Therapeutics (SLN) Receives a Buy from H.C. WainwrightMay 27, 2026 | theglobeandmail.comSilence Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 27, 2026 | businesswire.comSilence Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLNMay 18, 2026 | benzinga.comSilence Therapeutics to Participate in H.C. Wainwright BioConnect Investor ConferenceMay 13, 2026 | pharmiweb.comPSilence Therapeutics highlights recent business achievements and reports first quarter 2026 financial resultsMay 7, 2026 | msn.comSilence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?April 16, 2026 | zacks.comSilence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 5, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe AI Chip Sell-Off Looks Scary, But the Real Story May Be LiquidityBy Jeffrey Neal Johnson | July 7, 20262 Quantum Stocks That Could Challenge IonQ’s LeadershipBy Nathan Reiff | July 15, 2026SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right NowBy Bridget Bennett | June 28, 20263 Space Stocks That Could Outshine SpaceX After Its IPOBy Chris Markoch | July 14, 2026Apple and Broadcom Forge a Decade-Long Silicon FortressBy Jeffrey Neal Johnson | July 7, 2026IPHYF, SLN, ALT, and RLMD Company DescriptionsAltimmune NASDAQ:ALT$2.77 -0.07 (-2.46%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.81 +0.04 (+1.44%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Innate Pharma OTCMKTS:IPHYF$1.65 0.00 (0.00%) As of 07/24/2026Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Relmada Therapeutics NASDAQ:RLMD$5.18 -0.02 (-0.38%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.22 +0.04 (+0.87%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Silence Therapeutics NASDAQ:SLN$11.02 -0.43 (-3.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$10.82 -0.21 (-1.86%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
